Keytruda reimbursement boosts MSD’s R&D of follow-up drug

Sadye Matula

&#13 &#13 The government’s recognition of MSD’s Keytruda (pembrolizumab) for reimbursement as the initial-line treatment for lung most cancers has accelerated the company’s advancement of yet another oncology pipeline constructed from the spine of Keytruda. &#13 &#13 On Friday, the Ministry of Meals and Drug Security approved MSD to carry […]